Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114165 | 0.86 | CCR1 (0.44) | CCR1CCR8NOS3NOS2HRH4 | |
| SCHEMBL24134081 | 0.85 | CCR1 (0.43) | CCR1CCR8NOS3NOS2HRH4 | |
| SCHEMBL91367 | 0.83 | — | — | |
| SCHEMBL30201993 | 0.80 | CCR1 (0.52) | CCR1CCR8NOS3NOS2SMN1; SMN2 | |
| SCHEMBL24916774 | 0.80 | CCR1 (0.52) | CCR1CCR8NOS3NOS2SMN1; SMN2 | |
| SCHEMBL14082023 | 0.80 | CCR1 (0.52) | CCR1CCR8NOS3NOS2SMN1; SMN2 | |
| SCHEMBL15314267 | 0.80 | ALDH1A1 (0.40) | CCR1CCR8NOS3NOS2HRH4 | |
| SCHEMBL10144469 | 0.78 | KCNH2 (0.54) | CCR1CCR8NOS3NOS2SMN1; SMN2 | |
| SCHEMBL13197263 | 0.77 | CTH (0.44) | CCR1CCR8SMN1; SMN2MEN1KMT2A | |
| SCHEMBL943326 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513260-B2 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-20 | — | — | US | claimed |
| EP-2435420-B1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-04-03 | — | — | EP | claimed |
| US-20120190687-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG | 2012-07-26 | — | — | US | claimed |
| US-20110021539-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-01-27 | — | — | US | claimed |
| WO-2010136145-A1 | PYRAZINYLPYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | WO | claimed |
| EP-2654425-A2 | ECTOPARASITICIDAL ACTIVE SUBSTANCE COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-8513260-B2 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-20 | — | — | US | disclosed |
| EP-2435420-B1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-20120190687-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG | 2012-07-26 | — | — | US | disclosed |
| WO-2012084852-A2 | ECTOPARASITICIDAL ACTIVE SUBSTANCE COMBINATIONS | BAYER ANIMAL HEALTH GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20110021539-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2266973-A1 | Pyrazinylpyrazole | Bayer CropScience AG (DE) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010136145-A1 | PYRAZINYLPYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021539-A1 | Pyrazinylpyrazoles | CYP4F3, CYP4B1, CYP1A2 | CCR1 4016/4885CCR8 3088/4885NOS3 2702/4885 |
| US-20120190687-A1 | Pyrazinylpyrazoles | CYP4F3, CYP4B1, CYP1A2 | CCR1 4016/4885CCR8 3088/4885NOS3 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.